Description of Medical ServiceNon-invasive prenatal testing through the analysis of cell free fetal DNA is a major technological advancement in testing for fetal aneuploidy.
Description of Medical ConditionThe medical conditions relevant to the proposed service are conditions such as Down syndrome, Edward syndrome, Patau syndrome and Turner syndrome that arise where the number of chromosomes present in the patient is abnormal (aneuploidy). Prenatal screening is a routine medical service for a pregnant woman to evaluate her personal risk of fetal aneuploidy. These aneuploidies include but are not limited to; trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome).
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative
Previous Application Number1458 & 1461
Consultation SurveyConsultation Survey (PDF 305 KB)
Consultation Survey (Word 508 KB)
PICO ConfirmationRatified PICO Confirmation (PDF 794 KB)
Ratified PICO Confirmation (Word 694 KB)
Public Summary DocumentPublic Summary Document (PDF 1163 KB)
Public Summary Document (Word 1169 KB)
Meetings for this Application
PASC8 December 2016
ESC8 June 2018
MSAC26-27 July 2018
Stakeholder MeetingTuesday 6 November 2018, members of MSAC, clinicians with experience and expertise in obstetrics and gynaecology, pathology, clinical genetics and genetic counselling; representatives of the applicant; representatives from consumer organisations; and representatives from the Department of Health met to discuss Non-Invasive Prenatal Testing (NIPT) for Common Trisomies (21, 18 and 13). This was not an MSAC decision forum, but a meeting that would inform the issues considered by MSAC, following its July 2018 consideration of application 1492. The final minutes of this meeting are below.
Final Stakeholder Meeting Minutes (PDF 320 KB)
Final Stakeholder Meeting Minutes (Word 64 KB)